<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">34821555</PMID><DateRevised><Year>2021</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.70002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">e70002</ELocationID><Abstract><AbstractText>The alpha/B.1.1.7 SARS-CoV-2 lineage emerged in autumn 2020 in the United Kingdom and transmitted rapidly until winter 2021 when it was responsible for most new COVID-19 cases in many European countries. The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains. Here, we present a functional characterization of the alpha/B.1.1.7 variant and show an eightfold affinity increase towards human angiotensin-converting enzyme-2 (ACE-2). In accordance with this, transgenic hACE2 mice showed a faster disease progression and severity after infection with a low dose of B.1.1.7, compared to an early 2020 SARS-CoV-2 isolate. When challenged with sera from convalescent individuals or anti-RBD monoclonal antibodies, the N501Y variant showed a minor, but significant elevated evasion potential of ACE-2/RBD antibody neutralization. The data suggest that the single asparagine to tyrosine substitution remarkable rise in affinity may be responsible for the higher transmission rate and severity of the B.1.1.7 variant.</AbstractText><CopyrightInformation>© 2021, Bayarri-Olmos et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bayarri-Olmos</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Recombinant Protein and Antibody Laboratory, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnsen</LastName><ForeName>Laust Bruun</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, Måløv, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idorn</LastName><ForeName>Manja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Århus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinert</LastName><ForeName>Line S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Århus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosbjerg</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Recombinant Protein and Antibody Laboratory, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vang</LastName><ForeName>Søren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Cecilie Bo</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helgstrand</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, Måløv, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjelke</LastName><ForeName>Jais Rose</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, Måløv, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bak-Thomsen</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, Måløv, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paludan</LastName><ForeName>Søren R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Århus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garred</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2876-8586</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skjoedt</LastName><ForeName>Mikkel-Ole</ForeName><Initials>MO</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1306-6482</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CF20-0045</GrantID><Agency>Carlsbergfondet</Agency><Country/></Grant><Grant><GrantID>NFF205A0063505</GrantID><Agency>Novo Nordisk Fonden</Agency><Country/></Grant><Grant><GrantID>NNF20OC0063436</GrantID><Agency>Novo Nordisk Fonden</Agency><Country/></Grant><Grant><GrantID>NNF20SA0064201</GrantID><Agency>Novo Nordisk Fonden</Agency><Country/></Grant><Grant><GrantID>ERC-AdG ENVISION; 786602</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>0214-00001B</GrantID><Agency>Independent Research Fund Denmark</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword></KeywordList><CoiStatement>RB, LJ, MI, LR, AR, SV, CH, CH, JB, TB, SP, PG, MS No competing interests declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34821555</ArticleId><ArticleId IdType="doi">10.7554/eLife.70002</ArticleId><ArticleId IdType="pii">70002</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>